Athos Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Athos Therapeutics's estimated annual revenue is currently $1.7M per year.
- Athos Therapeutics's estimated revenue per employee is $77,500
- Athos Therapeutics's total funding is $28M.
Employee Data
- Athos Therapeutics has 22 Employees.
- Athos Therapeutics grew their employee count by 22% last year.
Athos Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Computational Biology | Reveal Email/Phone |
2 | VP, Analytical Chemistry | Reveal Email/Phone |
3 | Director | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | President, CEO | Reveal Email/Phone |
7 | Chairman & CMO | Reveal Email/Phone |
Athos Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Athos Therapeutics?
Developing precision therapeutics for patients with chronic inflammatory diseases incorporating artificial intelligence and machine learning algorithms
keywords:N/A$28M
Total Funding
22
Number of Employees
$1.7M
Revenue (est)
22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Athos Therapeutics News
2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a ...
... Nestle, Arena Pharmaceuticals, Gilead Sciences, Galapagos, MSD, Celltrion, Sublimity Therapeutics, Sandoz, Abbott Laboratories, and Athos Therapeutics.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.8M | 22 | -19% | N/A |
#2 | $3.1M | 22 | 5% | N/A |
#3 | $2.2M | 22 | -8% | N/A |
#4 | N/A | 22 | 10% | N/A |
#5 | $2.2M | 22 | 0% | N/A |